Roberto Moretti

Dr. Roberto Moretti


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
EPElisabetta Perrone
Elisabetta Perrone
MCMaria Lucia Calcagni
Maria Lucia Calcagni
Lucia LeccisottiLucia Leccisotti
Lucia Leccisotti
RMRoberto Moretti
Roberto Moretti
KGKriti Ghai
Kriti Ghai
RBRichard P. Baum
Richard P. Baum
Peptide Receptor Radionuclide Therapy (PRRT) offers radiomolecular precision medicine for somatostatin receptor (SSTR)-positive advanced neuroendocrine neoplasms (NEN). In cases resistant to Lutetium-177-labeled DOTATATE or DOTATOC PRRT, alpha-therapy with Actinium-225 labeled with SSTR antagonists like DOTA-LM3 can be a notable therapeutic option. This retrospective study aimed to assess [225Ac]Ac-DOTA-LM3 safety in advanced NEN patients (as monotherapy and with Lutetium-177 as TANDEM), survival, and follow-up duration. Thirty-five patients received a total of 57 [225Ac]Ac-DOTA-LM3 cycles (March 2022–September 2024): 24 monotherapies and 33 TANDEM therapies. The pancreas was the most common primary site (n = 19). PRRT-related toxicity was assessed, focusing on hematological, renal, and hepatic toxicity (Common Terminology Criteria for Adverse Events—CTCAE v5.0). Therapy was generally well tolerated, with mostly mild acute adverse events (primarily nausea, n = 8). Some new grade 3/4 long-term adverse events were reported after treatment: anemia grade 3 (n = 2), leukocytopenia grade 4 (n = 1), absolute neutrophil count reduction grade 3 (n = 1), thrombocytopenia grade 3 (n = 7), acute myeloid leukemia (n = 1), nephrotoxicity grade 3 (n = 2), and hepatotoxicity grade 3 (n = 2). During follow-up, 13 patients died (survival range 5–30 months); 22 patients were alive (follow-up range 1–18 months). Our retrospective analysis shows that [225Ac]Ac-DOTA-LM3 PRRT is relatively safe concerning acute and long-term toxicity and bears promising survival outcomes in patients progressing after [177Lu]Lu-DOTATATE or [177Lu]Lu-DOTATOC PRRT.

25 January 2024 in Applied Sciences
Verified
Journal Article
Open access
PDF file
ACAmedeo Capotosti
Amedeo Capotosti
RMRoberto Moretti
Roberto Moretti
MVMaria Vaccaro
Maria Vaccaro
CRCintia De Almeida Ribeiro
Cintia De Almeida Ribeiro
LPLorenzo Placidi
Lorenzo Placidi
LILuca Indovina
Luca Indovina
(1) Background: In 90Y-TARE treatments, lung-absorbed doses should be calculated according to the manufacturer’s instructions, using the MIRD-scheme. This scheme is derived from the assumption that 90Y-microspheres deliver the dose in a water-equivalent medium. Since the density of the lungs is quite different from that of the liver, the absorbed dose to the lungs could vary considerably, especially at the liver/lungs interface. The aim of this work is to compare the dosimetric results obtained by two dedicated software packages implementing a water-equivalent dose calculation and a Monte Carlo (MC) simulation, respectively. (2) Methods: An anthropomorphic IEC phantom and a retrospective selection of 24 patients with a diagnosis of HCC were taken into account. In the phantom study, starting from a 90Y-PET/CT acquisition, the liver cavity was manually fixed with a uniform activity concentration on PET series, while the lung compartment was manually expanded on a CT series to simulate a realistic situation in which the liver and lungs are adjacent. These steps were performed by using MIM 90Y SurePlan. Then, a first simulation was carried out with only the liver cavity filled, while a second one was carried out, in which the lung compartment was also manually fixed with a uniform activity concentration corresponding to 10% lung shunt fraction. MIM 90Y SurePlan was used to obtain Voxel S-Value (VSV) approach dose values; instead, Torch was used to obtain MC approach dose values for both the phantom and the patients. (3) Results: In the phantom study, the percentage mean dose differences (∆D%) between VSV and MC in the first and second simulation, respectively were found to be 1.2 and 0.5% (absolute dose variation, ∆D, of 0.7 and 0.3 Gy) for the liver, −56 and 70% (∆D of −0.3 and −16.2 Gy) for the lungs, and −48 and −60% (∆D of −4.3 and −16.5 Gy) for the Liver/Lungs Edge region. The patient study reports similar results with ∆D% between VSV and MC of 7.0%, 4.1% and 6.7% for the whole liver, healthy liver, and tumor, respectively, while the result was −61.2% for the left lung and −61.1% for both the right lung and lungs. (4) Conclusion: Both VSV and MC allowed accurate radiation dose estimation with small differences (50%) were observed for air-equivalent regions in the phantom simulation and the patient study.

25 April 2024 in Physica Medica
Verified
Journal Article
Closed access
GMGuenda Meffe
Guenda Meffe
CVClaudio Votta
Claudio Votta
GTGabriele Turco
Gabriele Turco
ECElena Chillè
Elena Chillè
MNMatteo Nardini
Matteo Nardini
LPLorenzo Placidi
Lorenzo Placidi

15 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
VSValentina Scolozzi
Valentina Scolozzi
ANAlberto Nicoletti
Alberto Nicoletti
ACAmedeo Capotosti
Amedeo Capotosti
FPFrancesca Romana Ponziani
Francesca Romana Ponziani
STSilvia Taralli
Silvia Taralli
MCMaria Lucia Calcagni
Maria Lucia Calcagni
Purpose: To prospectively investigate dynamic 13N-ammonia PET-CT for evaluating early treatment response and predicting prognosis in advanced hepatocellular carcinoma (HCC) patients who have undergone antiangiogenic therapy. Methods: Dynamic 13N-ammonia PET-CT was performed in 23 advanced HCC patients before antiangiogenic therapy (baseline) and in 18/23 patients after 8-10 weeks of treatment (post-therapy). At kinetic PET-CT analysis, mean, maximum, and peak values of K1 (mL/cm3/min) and k2 (min−1) were estimated in HCC lesions and non-neoplastic liver using cardiologic 13N-ammonia PET-CT in 15 patients without any liver diseases as normal controls. Outcome endpoints were treatment response after 8–10 weeks assessed by contrast-enhanced CT, progression-free survival (PFS), and overall survival (OS). Results: At both baseline and post-therapy PET-CT, all kinetic PET parameters were significantly higher (p < 0.05) in HCC lesions than in non-neoplastic and healthy liver of HCC patients and controls. According to mRECIST criteria, 13/18 patients (72.2%) were responders (1 CR, 1 PR, and 11 SD), and 5/18 patients (27.8%) were non-responders (PD), with no significant differences in baseline and post-therapy PET parameters between the two groups. At follow-up (median: 14.2 months), 15/18 patients (83.3%) experienced radiological progression, and 14/18 (77.8%) died (7/14 within 12 months from treatment). The nine earlier-progression patients (within 6 months from treatment) showed significantly lower baseline K1mean in HCC lesions than all nine patients with later or no-progression (p = 0.03). Patients still alive 12 months after treatment (n = 11) showed significantly lower post-therapy K1mean (p = 0.05), K1max (p = 0.05), and K1peak (p = 0.03) in non-neoplastic liver than patients with shorter OS (n = 7). Conclusions: In advanced HCC patients treated with antiangiogenic agents, kinetic parameters from baseline and post-therapy 13N-ammonia PET-CT may predict early disease progression and survival. PET-CT seems not able to discriminate responders and non-responders after 8-10 weeks of treatment, suggesting the need for future and larger studies after a longer treatment period.

29 May 2026 in Physica Medica
Verified
Journal Article
Open access
CCClelia Cotena
Clelia Cotena
CMCarolina Mainardi
Carolina Mainardi
SCStefania Clemente
Stefania Clemente
AVAntonio Varallo
Antonio Varallo
SGSalvatore Grasso
Salvatore Grasso
ASAntonio Sarno
Antonio Sarno
To characterize the image quality and dose level of a cone-beam CT (CBCT) scanner dedicated to maxillo-facial intra-surgical navigation. Acquisition protocols for head imaging of average pediatric and adult patients were investigated. The detector response curve and the modulation transfer function (MTF) were assessed. The 3D image quality was evaluated using a commercial Catphan604 phantom in terms of accuracy of Hounsfield Unit (HU) estimates and slice uniformity. The MTF and the noise power spectrum (NPS) were assessed over the 3D reconstructed images. The weighted cone-beam dose index (CBDIw) was used for dosimetric benchmarking, and TLD chips placed in two anthropomorphic phantoms provided insight into the patient dose distribution. The detector exhibited a response curve with a double natural logarithmic behavior and spatial resolutions up to 6.3 mm-1. The 3D spatial resolution ranged from 0.70 mm-1 at the scanner isocenter, for the pediatric protocol, to 0.46 mm-1 at 7 cm from the isocenter for the adult protocol. Due to beam hardening and the scatter, discrepancies between expected and measured HU were observed, in particular for positive HU values (i.e. those for acrylic, bone, delrin and teflon inserts). The CBDIw and dose distribution within anthropomorphic phantoms provided a dosimetric benchmark for the scanner. This study characterized a CBCT scanner in maxillo-facial surgery navigation. The findings support the definition of quality assurance protocols, providing methodologies and reference values for image quality and dose, while also highlighting limitations in spatial resolution and accuracy relevant for quantitative evaluations in clinical practice.

1 June 2023 in Journal of Radiological Protection
Verified
Journal Article
Closed access
LILuca Indovina
Luca Indovina
RMRoberto Moretti
Roberto Moretti
LBLaura Breschi
Laura Breschi
DCDavide Cusumano
Davide Cusumano
GMGuenda Meffe
Guenda Meffe
ACAmedeo Capotosti
Amedeo Capotosti
Introduction: interventional radiology workers are potentially exposed to high levels of ionizing radiation, therefore preventive dose estimation is mandatory for the correct risk classification of staff. Effective dose (ED) is a radiation protection quantity strictly related to the secondary air kerma (K S), using appropriate multiplicative conversion factors (ICRP 106). The aim of this work is to evaluate the accuracy of K S estimated from physically measurable quantities such as dose-area product (DAP) or fluoroscopy time (FT). Methods: radiological units (n = 4) were characterized in terms of primary beam air kerma and DAP-meter response, consequently defining a DAP-meter correction factor (CF) for each unit. K S, scattered from an anthropomorphic phantom and measured by a digital multimeter, was then compared with the value estimated from DAP and FT. Different combinations of tube voltages, field sizes, current and scattering angles were used to simulate the variation of working conditions. Further measurements were performed to estimate the couch transmission factor for different phantom placements on the operational couch, defining a CF as the mean transmission factor. Results: when no CFs were applied, the measured K S showed a median percentage difference of between 33.8% and 115.7% with respect to K S evaluated from DAP, and between −46.3% and 101.8% for K S evaluated from FT. By contrast, when previously defined CFs were applied to the evaluated K S, the median percentage difference between the measured K S and the value evaluated from DAP ranged from between −7.94% and 15.0%, and between −66.2% and 17.2% for that evaluated from FT. Conclusion: when appropriate CF are applied, the preventive ED estimation from the median DAP value seems to be more conservative and easier to obtain with respect to the one obtained from the FT value. Further measurements should be performed with a personal dosimeter during routine activities to assess the proper K S to ED conversion factor.